Welcome to our dedicated page for ASTERA LABS SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Astera Labs, Inc. SEC filings page for ticker ALAB provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed semiconductor company focused on rack-scale AI infrastructure, Astera Labs uses these filings to report material events, financial results, and other information relevant to investors.
Recent filings include multiple Form 8-K reports. Some of these 8-Ks furnish press releases covering quarterly financial results, described under Item 2.02, “Results of Operations and Financial Condition.” Others report material events such as Astera Labs entering into a definitive agreement to acquire aiXscale Photonics GmbH, disclosed under Item 8.01, “Other Events.” These documents link directly to the company’s public communications and provide the formal regulatory record.
Through this page, users can locate Astera Labs’ quarterly earnings information as furnished in Form 8-K, along with other current reports that explain significant developments in the business. While the examples provided reference 8-K filings, the broader filings history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and other forms that detail the company’s financial condition, risk factors, and governance matters.
Stock Titan enhances these filings with AI-powered summaries that help explain key points from lengthy documents, such as earnings releases or transaction announcements. Real-time updates from EDGAR allow investors to see new ALAB filings as they appear, while AI-generated highlights can make it easier to understand how specific disclosures relate to Astera Labs’ rack-scale AI connectivity strategy, collaborations with hyperscalers, and acquisitions such as the aiXscale Photonics agreement.
Astera Labs reports rapid expansion and a move to profitability, highlighting both opportunity and risk. Revenue grew from $115.8 million in 2023 to $396.3 million in 2024 and $852.5 million in 2025, while net income reached $219.1 million after prior-year losses. The company focuses on semiconductor-based connectivity for cloud and AI infrastructure, with products like Aries PCIe/CXL retimers, Taurus Ethernet modules, Leo CXL memory controllers, and Scorpio fabric switches, all tied together by its COSMOS software suite. Growth is heavily concentrated: in 2025, one end customer generated more than 70% of revenue and the top three end customers 86%. As of June 30, 2025, non‑affiliate common stock held a $13.2 billion market value at $90.42 per share, and 170,214,503 shares were outstanding on January 31, 2026. Management flags key risks including AI adoption uncertainty, reliance on TSMC and a small set of manufacturing partners, exposure to U.S.–China trade and export controls, cybersecurity threats, and intense competition from larger chipmakers.
Astera Labs, Inc. Chief Executive Officer Mohan Jitendra reported automatic sales of 94,971 shares of common stock on February 17, 2026. The filing states these shares were sold to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units under a pre-arranged “sell to cover” election, and it notes the transactions were not discretionary trades by the reporting person.
After these sales, Jitendra continues to hold 1,452,739 shares of common stock directly. The filing also reports additional indirect holdings through a living trust and several estate-planning trusts, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. President and COO Gajendra Sanjay reported open-market sales of 94,971 shares of common stock on February 17, 2026. The shares were sold at weighted-average prices between
According to the disclosure, these shares were required to be sold to satisfy tax withholding obligations tied to vesting and settlement of previously granted restricted stock units, under a pre-arranged “sell to cover” election, and do not represent discretionary trades by Sanjay.
After these sales, he holds 1,531,301 shares directly. Estate-planning trusts associated with him hold an additional 5,864,213 shares in Trust 1, 695,000 shares in Trust 2, and 695,000 shares in Trust 3, for which he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. Chief Financial Officer Michael Truett reported automatic sales of 12,001 shares of common stock on February 17, 2026 to satisfy tax withholding from vested restricted stock units under a pre-arranged sell-to-cover election. Sale prices ranged around $122–$126 per share. Truett continues to hold 192,083 shares directly, while 450,281 additional shares are held by the Tate 1997 Living Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported automatic sales of 4,849 shares of common stock on February 17, 2026. The Form 4 notes these open-market sales were made solely to cover tax withholding obligations from vesting restricted stock units. After these transactions, he directly held 138,084 shares of common stock.
Astera Labs, Inc. submitted a Form 144 notice reporting proposed sales of Common Stock tied to the vesting of restricted stock units on
The filing lists prior sales by Philip Mazzara: 4,620 shares on
Astera Labs filed a Form 144 disclosing a sale of 11,430 shares of common stock by Michael Truett Tate on
Astera Labs insider filing to sell shares. The Form 144 discloses an intended sale of 94,971 shares of common stock tied to the vesting of restricted stock units on
Astera Labs disclosed a proposed sale of 94,971 shares of common stock tied to the vesting of restricted stock units on
Astera Labs, Inc. reported an equity award for its Chief Financial Officer, Tate Michael Truett. On February 6, 2026, he received 11,787 restricted stock units of Common Stock at a price of $0 per share, increasing his directly held Common Stock to 204,084 shares.
The RSUs vest 25% on February 15, 2027, with the remaining units vesting in 12 equal quarterly installments, conditioned on his continued service. Separately, 450,281 Common Stock shares are held indirectly by the Tate 1997 Living Trust, where he is a trustee and disclaims beneficial ownership except for any pecuniary interest.